Non Muscle Invasive Bladder Cancer Pipeline Summary

DelveInsight’s, “Non Muscle Invasive Bladder Cancer - Pipeline Insight, 2026” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Non Muscle Invasive Bladder Cancer: Understanding

Non Muscle Invasive Bladder Cancer: Overview

Non-muscle invasive bladder cancer (NMIBC) is a type of cancer that affects the tissue lining the inner surface of the bladder without involving the bladder muscle. It is the most common form of bladder cancer, accounting for approximately 70-80% of all diagnosed cases. Bladder cancer is the 6th most common cancer in the United States, with nearly 81,000 new diagnoses in 2020. The disease is more prevalent in males than females, with risk factors including smoking, exposure to certain chemicals, and chronic bladder infections. While NMIBC typically has a better prognosis compared to muscle-invasive bladder cancer (MIBC), it still presents a significant health challenge due to its potential for recurrence and progression, making early detection and effective treatment crucial.

Bladder cancer may present with a variety of symptoms, although some individuals may not experience any noticeable signs, especially in the early stages. It is important not to ignore potential symptoms, as early detection plays a crucial role in improving treatment outcomes. The most common symptom of bladder cancer is hematuria, or blood in the urine, which often occurs without pain and can be either visible or microscopic. Other common symptoms include frequent urination, an urgent need to urinate, and a sensation of incomplete bladder emptying. Painful urination (dysuria) can also be a sign, along with discomfort or pain in the lower abdomen or pelvic region. In more advanced stages, patients may experience back pain, which could indicate the spread of cancer. While these symptoms can be caused by conditions other than bladder cancer, such as urinary tract infections or kidney stones, it is important for individuals experiencing any of these signs to seek medical attention promptly. Early diagnosis and intervention are key to managing bladder cancer effectively.

The diagnosis of bladder cancer is primarily confirmed through cystoscopic examination and histological evaluation of resected tissue. In some cases, approximately 4%, bladder cancer is discovered incidentally, often during imaging procedures conducted to investigate non-urological symptoms. However, traditional white light cystoscopy (WLC) has a limited detection rate, with some studies reporting sensitivity as low as 60%. To improve detection, enhanced visualization techniques have been developed, such as hexyl aminolevulinate (HAL)-photodynamic diagnosis (PDD) and narrow band imaging (NBI), both of which have shown strong evidence of improving tumor identification and early recurrence detection. Blue light cystoscopy (BLC), or PDD, involves the preoperative intravesical instillation of HAL, a photosensitizer that preferentially accumulates in neoplastic cells. When exposed to blue light, these cells emit red fluorescence, making them more visible and aiding in the accurate identification of malignant lesions. These advanced diagnostic methods have significantly improved the detection of bladder cancer, especially in its early stages, and offer better management of the disease.

The primary treatments for non-muscle-invasive bladder cancer (NMIBC), where cancer cells are confined to the inner lining of the bladder, include surgery, immunotherapy, and intravesical chemotherapy. Surgery is often the first line of treatment and is commonly performed through a procedure known as transurethral resection of bladder tumor (TURBT). This minimally invasive surgery is typically done under general anesthesia during a cystoscopy and takes approximately 15 to 40 minutes, with no external incisions required. TURBT allows for the removal of visible tumors from the bladder lining. In addition to surgery, immunotherapy is frequently used, particularly Bacillus Calmette-Guérin (BCG) therapy. BCG, originally a vaccine for tuberculosis, is instilled directly into the bladder where it stimulates the body's immune system to recognize and fight bladder cancer cells. This treatment helps reduce the risk of recurrence and can delay or prevent the cancer from becoming invasive. Intravesical chemotherapy may also be used in combination with these treatments to target any remaining cancer cells and lower the chance of recurrence. Together, these approaches form a comprehensive treatment strategy to manage non-muscle-invasive bladder cancer effectively.

"Non Muscle Invasive Bladder Cancer- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Non Muscle Invasive Bladder Cancer pipeline landscape is provided which includes the disease overview and Non Muscle Invasive Bladder Cancer treatment guidelines. The assessment part of the report embraces, in depth Non Muscle Invasive Bladder Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Non Muscle Invasive Bladder Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Non Muscle Invasive Bladder Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Non Muscle Invasive Bladder Cancer.

Non Muscle Invasive Bladder Cancer Emerging Drugs Chapters

This segment of the Non Muscle Invasive Bladder Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Non Muscle Invasive Bladder Cancer Emerging Drugs

• TAR-210: Johnson & Johnson Innovative Medicine

TAR-210 is an investigational, sustained-release intravesical formulation of gemcitabine being developed by Johnson & Johnson for the treatment of non-muscle invasive bladder cancer (NMIBC). It utilizes a novel intravesical drug delivery system that continuously releases gemcitabine directly into the bladder over several weeks, maintaining prolonged local drug exposure while minimizing systemic toxicity and reducing the need for frequent intravesical instillations. TAR-210 is being evaluated as both a monotherapy and in combination with cetrelimab in patients with intermediate- and high-risk NMIBC, including those with BCG-unresponsive disease. Clinical studies have demonstrated promising complete response rates, durable responses, and a favorable safety profile. Currently, the drug is in Phase III stage of its development for the treatment of Non Muscle Invasive Bladder Cancer.

• APL-1202: Asieris Pharmaceuticals

APL-1202 is an innovative oncology drug developed by Asieris Pharmaceuticals, following over a decade of research and the in-licensing of patented technology from Johns Hopkins University in the United States. It is the first-in-class, oral, and reversible Methionine Aminopeptidase 2 (MetAP2) inhibitor, currently undergoing pivotal Phase III clinical trials for Non-Muscle Invasive Bladder Cancer (NMIBC). At the same time, APL-1202 is also being developed for preoperative neoadjuvant treatment of muscle invasive bladder cancer (MIBC). The APL-1202 project was granted support by the National Major New Drug Innovation Programs for the 12th and 13th five-year plan period in 2015 and 2018, respectively. Currently, the drug is in Phase III stage of its development for the treatment of Non Muscle Invasive Bladder Cancer.

• TLD-1433: Protara Therapeutics

TLD-1433 is a non-toxic ruthenium-based coordination-complex and photosensitizer, with potential antineoplastic activity upon photodynamic therapy (PDT). Upon intravesical administration, light-activated photodynamic compound (PDC) TLD-1433 targets and binds to transferrin (Tf) and is subsequently taken up by Tf receptors which are located on tumor cells. Upon exposure to green light (525nm), TLD-1433 becomes activated locally and induces the generation of reactive oxygen species (ROS) and singlet oxygen. The release of free radicals may induce apoptosis and destroy the tumor cells. Cancer cells have many more Tf receptors than normal cells. Currently, the drug is in Phase II stage of its development for the treatment of Non Muscle Invasive Bladder Cancer.

Further product details are provided in the report……..

Non Muscle Invasive Bladder Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Non Muscle Invasive Bladder Cancer drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Non Muscle Invasive Bladder Cancer
• There are approx. 20+ key companies which are developing the therapies for Non Muscle Invasive Bladder Cancer. The companies which have their Non Muscle Invasive Bladder Cancer drug candidates in the most advanced stage, i.e. Phase III include, Johnson & Johnson Innovative Medicine.

• Phases

DelveInsight’s report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Non Muscle Invasive Bladder Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Non Muscle Invasive Bladder Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Non Muscle Invasive Bladder Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Non Muscle Invasive Bladder Cancer drugs.

Non Muscle Invasive Bladder Cancer Report Insights

• Non Muscle Invasive Bladder Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Non Muscle Invasive Bladder Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Non Muscle Invasive Bladder Cancer drugs?
• How many Non Muscle Invasive Bladder Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Non Muscle Invasive Bladder Cancer?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Non Muscle Invasive Bladder Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Non Muscle Invasive Bladder Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Johnson & Johnson Innovative Medicine
• Asieris Pharmaceuticals
• Pfizer
• Theralase Technologies
• Protara Therapeutics
• Zhuhai Beihai Biotech Co., Ltd
• Vaxiion Therapeutics
• Aura Biosciences
• Ractigen Therapeutics
• Tyra Biosciences
• Hoffmann-La Roche
• SURGE Therapeutics
• CG Oncology, Inc.
• Trigone Pharma Ltd.
• Merck Sharp & Dohme LLC

Key Products

• TAR-200
• APL-1202
• PF-06801591
• TLD 1433
• TARA-002
• BH011
• VAX 014
• AU-011
• RAG-01
• TYRA-300
• Eciskafusp Alfa
• STM-416
• CG0070
• NDV01
• V940